Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

578.65 -29.84 (-4.90%)
Delayed Quote Updated: 12:19 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call ↗
United Therapeutics (NASDAQ:UTHR) reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission... 
Via MarketBeat
Topics Earnings Supply Chain
News headline image
United Therapeutics (UTHR) Q3 2026 Earnings Call Transcript ↗
Tyvaso DPI growth lifted revenue while R&D spending weighed on profit. 
Via The Motley Fool
Topics Earnings
United Therapeutics (NASDAQ:UTHR) Revenue Beats as R&D Costs Weigh on Earnings ↗
Via Chartmill
News headline image
United Therapeutics Announces Buydown of Ralinepag Royalty
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗
Via Chartmill
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
Via Chartmill
News headline image
United Therapeutics (NASDAQ:UTHR) beats Q3 2026 sales expectations, stock soars
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q3 2026 results topping the market’s revenue expectations, with revenue up 4.1% year on year... 
Via StockStory
News headline image
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should ... 
Via StockStory
News headline image
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
News headline image
2 healthcare stocks to keep an eye on and 1 that underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
News headline image
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Market-Beating Stocks for Long-Term Investors
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
2 Cash-Producing Stocks on Our Watchlist and 1 We Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
From United Therapeutics
Via Business Wire
News headline image
3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
Since April 2026, United Therapeutics has been in a holding pattern, posting a small loss of 4.2% while floating around $541.72. The stock also fell short of... 
Via StockStory
News headline image
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
Via StockStory
Topics Intellectual Property
News headline image
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe... 
Via StockStory
News headline image
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
From United Therapeutics
Via Business Wire
News headline image
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled t... 
Via StockStory
Topics Intellectual Property
News headline image
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors... 
Via MarketBeat
News headline image
Why United Therapeutics (UTHR) Shares Are Falling Today
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of t... 
Via StockStory
News headline image
1 Cash-Heavy Stock to Target This Week and 2 We Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o... 
Via StockStory
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.